H. Lundbeck A/S
Company Snapshot
Founded: 1915
Entity Type: Public
Employees: 5,461
Region: U.S.
Revenue: $3,193.1 Millions
Revenue Year: 2025
Headquarter: Valby, Denmark
Key Geographics: U.S., Europe, International Markets
Corporate Address: Ottiliavej 9 Valby 2500 Denmark Tel. +45-4371-4270 www.lundbeck.com
Company Overview
Lundbeck is a biopharmaceutical company focusing exclusively on brain health, including neurological and psychiatric diseases. Its strategic brands include Rexulti (treatment of major depressive disorder and agitation that may happen with dementia), Brintellix/Trintellix (treatment of major depressive disorder), Abilify long-acting injectable franchise (treatment of schizophrenia or for maintenance monotherapy treatment of bipolar I disorder in adults), and Vyepti (preventive treatment of migraine in adults). Lundbeck has a presence in more than 20 countries and markets its products in more than 80 countries.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
H. Lundbeck A/S In News
Company's Business Segments
- Strategic Brands : Rexulti, Brintellix, Abilify Maintena, Asimtufii, Vyepti, Others.
- Mature Brands : Cipralex, Lexapro, Sabril, Other Pharmaceuticals.
Applications/End User Industries
- Pharmaceuticals
- Healthcare
- Biotechnology
- Research and Development